825 INDUSTRIAL ROAD, SAN CARLOS, CA
Investor Presentation
Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
Corporate Overview June 2026
Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
Annual Report to Security Holders
Director Retirement - Wendy Yarno Not Standing for Re-Election
Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence